Probiotic Supplementation for Neonates with congenital Gastrointestinal Surgical Conditions

Shripada Rao

doi:10.26182/grcj-1y24

Probiotic Supplementation for Neonates with congenital Gastrointestinal Surgical Conditions

Shripada Rao

Paediatrics

Research output: Thesis › Doctoral Thesis

93 Downloads (Pure)

Abstract

Neonates with congenital gastrointestinal surgical conditions (CGISCs) are at risk of gut dysbiosis, infections and suboptimal neurodevelopment. There is biological plausibility that attenuating dysbiosis may improve their outcomes. Our prospective study (n=73) found that compared to healthy infants, neonates with CGISCs had lower levels of stool bifidobacteria and biologically important short-chain fatty acids (SCFA). Hence, we conducted a pilot RCT (n=61), which found that bifidobacteria (probiotic) supplementation attenuated dysbiosis, and improved stool SCFA levels and head growth. We then provided guidelines for conducting large RCTs to evaluate the role of probiotics in improving their clinical and neurodevelopmental outcomes.

Original language	English
Qualification	Doctor of Philosophy
Awarding Institution	The University of Western Australia
Supervisors/Advisors	Patole, Sanjay, Supervisor Simmer, Karen, Supervisor
Thesis sponsors	Australian Government Research Training Program
Award date	25 May 2022
DOIs	https://doi.org/10.26182/grcj-1y24
Publication status	Unpublished - 2022

Access to Document

10.26182/grcj-1y24

THESIS - DOCTOR OF PHILOSOPHY - RAO, Shripada - 2022
This work is protected by Copyright. You may print or download ONE copy of this document for the purpose of your own non-commercial research or study. Any other use requires permission from the copyright owner. The Copyright Act requires you to attribute any copyright works you quote or paraphrase.

Cite this

@phdthesis{c76f69acd0974c9895076a8c89789c22,

title = "Probiotic Supplementation for Neonates with congenital Gastrointestinal Surgical Conditions",

abstract = "Neonates with congenital gastrointestinal surgical conditions (CGISCs) are at risk of gut dysbiosis, infections and suboptimal neurodevelopment. There is biological plausibility that attenuating dysbiosis may improve their outcomes. Our prospective study (n=73) found that compared to healthy infants, neonates with CGISCs had lower levels of stool bifidobacteria and biologically important short-chain fatty acids (SCFA). Hence, we conducted a pilot RCT (n=61), which found that bifidobacteria (probiotic) supplementation attenuated dysbiosis, and improved stool SCFA levels and head growth. We then provided guidelines for conducting large RCTs to evaluate the role of probiotics in improving their clinical and neurodevelopmental outcomes.",

keywords = "Neonate, Surgery, Dysbiosis, Probiotic, Bifidobacteria, Gut, Neurodevelopment, Microbiota",

author = "Shripada Rao",

year = "2022",

doi = "10.26182/grcj-1y24",

language = "English",

school = "The University of Western Australia",

}

TY - THES

T1 - Probiotic Supplementation for Neonates with congenital Gastrointestinal Surgical Conditions

AU - Rao, Shripada

PY - 2022

Y1 - 2022

N2 - Neonates with congenital gastrointestinal surgical conditions (CGISCs) are at risk of gut dysbiosis, infections and suboptimal neurodevelopment. There is biological plausibility that attenuating dysbiosis may improve their outcomes. Our prospective study (n=73) found that compared to healthy infants, neonates with CGISCs had lower levels of stool bifidobacteria and biologically important short-chain fatty acids (SCFA). Hence, we conducted a pilot RCT (n=61), which found that bifidobacteria (probiotic) supplementation attenuated dysbiosis, and improved stool SCFA levels and head growth. We then provided guidelines for conducting large RCTs to evaluate the role of probiotics in improving their clinical and neurodevelopmental outcomes.

AB - Neonates with congenital gastrointestinal surgical conditions (CGISCs) are at risk of gut dysbiosis, infections and suboptimal neurodevelopment. There is biological plausibility that attenuating dysbiosis may improve their outcomes. Our prospective study (n=73) found that compared to healthy infants, neonates with CGISCs had lower levels of stool bifidobacteria and biologically important short-chain fatty acids (SCFA). Hence, we conducted a pilot RCT (n=61), which found that bifidobacteria (probiotic) supplementation attenuated dysbiosis, and improved stool SCFA levels and head growth. We then provided guidelines for conducting large RCTs to evaluate the role of probiotics in improving their clinical and neurodevelopmental outcomes.

KW - Neonate

KW - Surgery

KW - Dysbiosis

KW - Probiotic

KW - Bifidobacteria

KW - Gut

KW - Neurodevelopment

KW - Microbiota

U2 - 10.26182/grcj-1y24

DO - 10.26182/grcj-1y24

M3 - Doctoral Thesis

ER -

Probiotic Supplementation for Neonates with congenital Gastrointestinal Surgical Conditions

Abstract

Access to Document

Fingerprint

Cite this